Diagnosis and Treatment of Biliary Tract Cancers
Episodes
Specialty:
All
All AI for Oncology Biosimilars Brain Cancer Breast Cancer CAR T-Cell Therapy Disparities in Cancer Care Gastrointestinal Cancer Genitourinary Cancers Global Oncology Graft-vs-Host Disease Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care
EP. 1: Overview on Biliary Tract Cancers and Their Rising Incidence By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Eugene J. Koay, MD, PhD, MD Anderson Cancer Center, Rachna T. Shroff, MD, MS, FASCO, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Expert panelists open their discussion on biliary tract cancers by identifying various subsets and noting the growing incidence of these diseases.
EP. 2: Clinical Scenario: Diagnostic Strategies to Identify Biliary Tract Cancers By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Eugene J. Koay, MD, PhD, MD Anderson Cancer Center, Rachna T. Shroff, MD, MS, FASCO, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Centering focus on a patient scenario, panelists break down mainstay diagnostic strategies used to identify biliary tract cancers.
EP. 3: Optimizing the Staging of Biliary Tract Cancers By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Eugene J. Koay, MD, PhD, MD Anderson Cancer Center, Rachna T. Shroff, MD, MS, FASCO, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Focused conversation on the optimal workup and staging of biliary tract cancers within the current paradigm.
EP. 4: Advent of Molecular Testing in Biliary Tract Cancers By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Eugene J. Koay, MD, PhD, MD Anderson Cancer Center, Rachna T. Shroff, MD, MS, FASCO, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Key opinion leaders review the advent of molecular testing in biliary tract cancers and consider its impact on informing treatment decisionmaking.
EP. 5: Biliary Tract Cancers: Surgical and Perioperative Treatment Strategies By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Eugene J. Koay, MD, PhD, MD Anderson Cancer Center, Rachna T. Shroff, MD, MS, FASCO, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Moving on to identify specific treatment modalities, panelists discuss the surgical and perioperative strategies used to manage biliary tract cancers.
EP. 6: Liver-Directed Treatment Strategies in Biliary Tract Cancers By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Eugene J. Koay, MD, PhD, MD Anderson Cancer Center, Rachna T. Shroff, MD, MS, FASCO, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University A comprehensive review of liver-directed therapies available to aid in the management of biliary tract cancers.
EP. 7: Role for Liver Transplant in Biliary Tract Cancers By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Eugene J. Koay, MD, PhD, MD Anderson Cancer Center, Rachna T. Shroff, MD, MS, FASCO, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University A brief discussion on the continued role of liver transplant in biliary tract cancers and when it is appropriate to consider a patient for this procedure.
EP. 8: Standard of Care Systemic Therapies for Biliary Tract Cancers By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Eugene J. Koay, MD, PhD, MD Anderson Cancer Center, Rachna T. Shroff, MD, MS, FASCO, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Key opinion leaders in the field of biliary tract cancers highlight mainstay systemic therapy regimens within the treatment paradigm.
EP. 9: TOPAZ-1: Chemotherapy + Durvalumab in Biliary Tract Cancers By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Eugene J. Koay, MD, PhD, MD Anderson Cancer Center, Rachna T. Shroff, MD, MS, FASCO, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Centering discussion on the TOPAZ-1 trial of chemotherapy in combination with durvalumab, panelists consider how this regimen has impacted clinical practice.
EP. 10: Biliary Tract Cancers: Combination Strategies With Immune Checkpoint Inhibitors By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Eugene J. Koay, MD, PhD, MD Anderson Cancer Center, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University An overview on novel treatment strategies in biliary tract cancers combining immune checkpoint inhibitors with various targeted agents.
EP. 11: Novel Targeted Therapies Under Investigation in Biliary Tract Cancers By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Eugene J. Koay, MD, PhD, MD Anderson Cancer Center, Rachna T. Shroff, MD, MS, FASCO, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Comprehensive insight on novel targeted agents under investigation in the setting of biliary tract cancers.
EP. 12: The Evolving Treatment Landscape of Biliary Tract Cancers By Milind Javle, MD, The University of Texas MD Anderson Cancer Center, Eugene J. Koay, MD, PhD, MD Anderson Cancer Center, Rachna T. Shroff, MD, MS, FASCO, Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Closing out their discussion on biliary tract cancers, expert panelists share key takeaways and excitement for the evolving treatment paradigm.
